Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils; instruments, such as labeling, bar coding, capping, de-capping, auditing, sealing, peeling, piercing tubes, and plates. The Life Sciences Services segment offers genomic services and sample repository solutions, including on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting; and informatics provides sample intelligence software solutions, which support laboratory workflow scheduling for life science tools and instrument work cells, sample, inventory and logistics, environmental and temperature monitoring, clinical trial and consent management, and planning, data management, virtualization and visualization of sample collections. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: https://www.azenta.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2024 | $64.00 | Hold | Jefferies |
| 2/1/2024 | $61.00 → $79.00 | Buy | B. Riley Securities |
| 7/19/2023 | Mkt Perform | Raymond James | |
| 5/10/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 2/9/2023 | $65.00 → $60.00 | Overweight → Equal-Weight | Stephens |
| 1/3/2023 | $60.00 → $62.00 | Outperform → In-line | Evercore ISI |
| 3/31/2022 | $106.00 | Buy | B. Riley Securities |
| 3/21/2022 | $100.00 | Outperform | Evercore ISI |
| 2/9/2022 | $155.00 → $115.00 | Buy | Needham |
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
8-K - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
10-Q - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
SD - Azenta, Inc. (0000933974) (Filer)
10-Q - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
Throughout the last three months, 5 analysts have evaluated Azenta (NASDAQ:AZTA), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 In the assessment of 12-month price targets, analysts unveil insights for Azenta, presenting an average target of $64.2, a high estimate of $75.00, and a low estimate of $53.00. A decline of 3.46% from the pr
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $52 to $53.
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries
Across the recent three months, 7 analysts have shared their insights on Azenta (NASDAQ:AZTA), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 2 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $70.43, along with a high estimate of $75.00 and a low estimate of $60.00. Experienc
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $75 to $69.
Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. The company reported quarterly sales of $159.134 million which missed the analyst consensus estimate of $159.887 million by 0.47 percent. This is a 7.23 percent increase over sales of $148.401 million the same period last year.
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and maintains $75 price target.
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and lowers the price target from $64 to $60.
Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00
B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously
Raymond James initiated coverage of Azenta with a rating of Mkt Perform
KeyBanc Capital Markets downgraded Azenta from Overweight to Sector Weight
Stephens downgraded Azenta from Overweight to Equal-Weight and set a new price target of $60.00 from $65.00 previously
Evercore ISI downgraded Azenta from Outperform to In-line and set a new price target of $62.00 from $60.00 previously
B. Riley Securities resumed coverage of Azenta with a rating of Buy and set a new price target of $106.00
Evercore ISI initiated coverage of Azenta with a rating of Outperform and set a new price target of $100.00
Needham reiterated coverage of Azenta with a rating of Buy and set a new price target of $115.00 from $155.00 previously
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
Ansa Biotechnologies, a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005146/en/Dr. Matthew McManus, Chair of the Board, Ansa Bio. (Photo: Business Wire) Dr. McManus brings decades of experience in the life sciences industry to the Board. He was most recently EVP and Chief Operating Officer at Azenta (NASDAQ:AZTA), a global life sciences tools, products, and services company. Prior to Azenta, Dr. McManus was Senior Vice President and Genera
CHELMSFORD, Mass., Jan. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has appointed Matthew McManus Chief Operating Officer effective January 17th. In this newly created role, Dr. McManus will oversee Life Sciences Products, Services, and all commercial operations of the business and will report directly to the CEO. "We are excited to have Matt join the Company as our COO," said Steve Schwartz, President and CEO of Azenta. "Matt brings decades of expertise in life sciences. His depth of knowledge and valuable perspective will enhance our leadership position in the markets we serve." Dr. McManus joins Azenta with over 25 years of experience in the life s
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin
BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutio
FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and MultiomicsFY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsPursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitabilityAnnounces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Fiscal Year 2024 Highlights: Q4'24 revenue growth o
BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 13, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solu
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i
BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of PacBio's Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads. Performed w
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
BURLINGTON, Mass., Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20. GENEWIZ Week will showcase our commitment to providing cutting-edge solutions to researchers worldwide through a series of workshops, an awards program, and engaging prizes and promotions. Registration for GENEWIZ Week 2024 is now open. The workshops are designed to help researchers overcome challenges and streamline their research, providing valuable insights and tips. Each virtual workshop will be followed by an interacti
BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 $ 166 9 % 4 % Organic growth 5 % Sample Management Solutions $ 81 $ 74 $ 75 9 % 7 % Multiomics $ 64 $ 62 $ 64 2 % (0) % B Medical Systems $ 29 $ 23 $ 27 25 % 7 % Diluted EPS Continuing Operations $ (0.12) $ (2.47) $ (0.04) 95 % nm Diluted EPS Total $ (0.12) $ (2.47) $ (0.02) 95 % nm Non-GAAP Diluted EPS Continuing Operations $ 0.16 $ 0.05 $ 0.13 nm 25 % Adjusted EBITDA - C
BURLINGTON, Mass., Aug. 5, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Monday, August 12, 2024. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our gl
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
SC 13G - Azenta, Inc. (0000933974) (Subject)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
SC 13D - Azenta, Inc. (0000933974) (Subject)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and MultiomicsFY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsPursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitabilityAnnounces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Fiscal Year 2024 Highlights: Q4'24 revenue growth o
BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 13, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solu
BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 $ 166 9 % 4 % Organic growth 5 % Sample Management Solutions $ 81 $ 74 $ 75 9 % 7 % Multiomics $ 64 $ 62 $ 64 2 % (0) % B Medical Systems $ 29 $ 23 $ 27 25 % 7 % Diluted EPS Continuing Operations $ (0.12) $ (2.47) $ (0.04) 95 % nm Diluted EPS Total $ (0.12) $ (2.47) $ (0.02) 95 % nm Non-GAAP Diluted EPS Continuing Operations $ 0.16 $ 0.05 $ 0.13 nm 25 % Adjusted EBITDA - C
BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 7, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling im
BURLINGTON, Mass., May 8, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2024. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2024 2023 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 159 $ 154 $ 148 3 % 7 % Organic growth 7 % Sample Management Solutions $ 74 $ 79 $ 71 (6) % 4 % Multiomics $ 62 $ 63 $ 62 (1) % (0) % B Medical Systems $ 23 $ 13 $ 15 81 % 51 % Diluted EPS Continuing Operations $ (2.47) $ (0.28) $ (0.03) nm nm Diluted EPS Total $ (2.47) $ (0.28) $ (0.07) nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.05 $ 0.02 $ (0.06) 102 % 184 %
BURLINGTON, Mass., May 1, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2024 earnings which ended on March 31, 2024, on Wednesday, May 8, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time. Conference call participants may access the call using the following online registration link. Registrants will receive a confirmation containing dial in details and a unique conference call code for entry. Analysts, investors, and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com
BURLINGTON, Mass., Feb. 7, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2023. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 154 $ 172 $ 178 (10) % (13) % Organic growth (15) % Sample Management Solutions $ 79 $ 82 $ 75 (3) % 5 % Multiomics $ 63 $ 61 $ 61 3 % 3 % B Medical Systems $ 13 $ 29 $ 42 (57) % (70) % Diluted EPS Continuing Operations $ (0.28) $ 0.05 $ (0.15) (690) % (79) % Diluted EPS Total $ (0.28) $ 0.06 $ (0.15) (591) % (79) % Non-GAAP Diluted EPS Continuing Operations $
BURLINGTON, Mass., Jan. 25, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2024 earnings which ended on December 31, 2023, on Wednesday, February 7, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 7, 2024, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-5171 for domestic callers and +1- 212-231-2906 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET
Q4'23 reported revenue growth of 25% year over year and 2% on an organic basisFY'23 reported revenue growth of 20% and down 1% on an organic basisQ4'23 generated positive free cash flow for the second consecutive quarterFiscal 2024 organic revenue growth expected to be 5-8% Committing to an additional $500 million in share repurchases in Fiscal 2024 BURLINGTON, Mass., Nov. 13, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2023. Quarter Ended Year Ended Dollars in millions, except per share data September 30, September 30, September 30, September 30, 2023 2022 Change 2023 2022 Change Revenue fro
BURLINGTON, Mass., Aug. 8, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2023. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 166 $ 148 $ 133 12 % 25 % Organic growth 2 % Life Sciences Products $ 75 $ 59 $ 47 27 % 57 % Life Sciences Services $ 91 $ 90 $ 85 2 % 7 % Diluted EPS Continuing Operations $ (0.04) $ (0.03) $ (0.09) (35) % 59 % Diluted EPS Total $ (0.02) $ (0.07) $ (0.13) 67 % 82 % Non-GAAP Diluted EPS Continuing Operations $ 0.13 $ (0.06) $ 0.12 nm 12 % Adjusted EBITDA Continuing Operations $